Hydrocortisone therapy in meconium aspiration syndrome: a controlled study

Area of Science:

• Neonatalogy
• Pediatric Pulmonology
• Pharmacology

Background:

• Meconium aspiration syndrome (MAS) is a significant cause of respiratory distress in newborns.
• Glucocorticoids have been explored as a potential treatment to reduce inflammation and improve respiratory function in MAS.
• Evaluating the efficacy of glucocorticoids in MAS is crucial for optimizing neonatal care.

Purpose of the Study:

• To assess the effectiveness of hydrocortisone compared to placebo in treating infants diagnosed with meconium aspiration syndrome.
• To determine if hydrocortisone influences key respiratory parameters, need for ventilation, or survival rates in MAS.
• To investigate the impact of hydrocortisone on the duration of respiratory support and time to room air in affected infants.

Main Methods:

• A double-blind, placebo-controlled study was conducted with 35 infants suffering from MAS.
• Participants were randomized to receive either hydrocortisone or a lactose placebo.
• Key clinical outcomes including blood gas levels, ventilation requirements, survival, respiratory distress scores, and time to room air were monitored.

Main Results:

• No significant differences were observed between the hydrocortisone and placebo groups in arterial blood gases (Po2, Pco2, pH), A-aDo2 gradients, need for assisted ventilation, or survival rates.
• While control infants showed a significant decrease in respiratory distress scores by 48-72 hours, treated infants only showed improvement after 72 hours.
• Infants receiving hydrocortisone required significantly longer to be weaned to room air (68.9 hours) compared to the control group (36.6 hours).

Conclusions:

• Hydrocortisone treatment did not demonstrate efficacy in improving respiratory parameters or survival in infants with meconium aspiration syndrome.
• The use of hydrocortisone was associated with a prolonged duration for weaning infants to room air.
• Based on these findings, hydrocortisone is not recommended for the treatment of meconium aspiration syndrome in neonates.